PDCD1 and cancer: Since anti-PD-1/PD-L1 alone may increase the expression of CD73 on cancer cells, which will induce immunosuppression and reduce the therapeutic effect, the combination of PD-1 antibody and CD73 inhibitor (AB680) co-delivered by EBPs has achieved a synergistic antitumor effect.